Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin. (2003). Int. BRCA1/2 mutation has been reported to correlate with carboplatin hypersensitivity (Altwerger et al., 2017). Carboplatin hypersensitivity. Report of three cases. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Epub 2011 Jan 26. (2013). Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. A history of drug or food allergy, the presence of malignant ascites, and the cumulative carboplatin dose are three independent predictive factors of carboplatin hypersensitivity in this survey. Allergic and non-allergic ovarian cancer patients treated with carboplatin or carboplatin desensitization presented a similar life expectancy with a non significant advantage for the allergy desensitized patients. Keywords: 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. Close monitoring is warranted for patients with any one of these three risk factors who are receiving carboplatin. We found a higher incidence of carboplatin-related hypersensitivity among patients with advanced disease (stage IIIIV) with serous carcinoma and malignant ascites. Though the characteristics of carboplatin-related hypersensitivity reactions are widely reported, limited data are available regarding such reactions in different types of patients. Accessibility The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. This site uses cookies. doi: 10.1159/000055363, Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., et al. We assessed occurrence, incidence and severity of these events in key Roche clinical trials of PH IV/PH FDC SC, and did a timetrend analysis (by cycle) for metastatic BC (MBC) and early BC (EBC) studies. Up to 16% of patients with ovarian cancer who undergo treatment with carboplatin-containing regimens experience carboplatin-related hypersensitivity (Markman et al., 1999; Polyzos et al., 2001; Sliesoraitis and Chikhale, 2005). Our present findings confirmed these factors and identified other risk factors, including advanced disease, serous histology, and the presence of malignant ascites. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Gynecol. (2009). 66, 730. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Anticancer. J. Clin. Monitor. In the present study, 61 patients with carboplatin-related hypersensitivity were rechallenged with carboplatin. doi: 10.1006/gyno.2001.6519, Gadducci, A., Tana, R., Teti, G., Zanca, G., Fanucchi, A., and Genazzani, A. R. (2008). The cumulative incidence of severe carboplatin-related hypersensitivity was 1% after 15 cycles and 2% after 24 cycles, with a plateau beyond this cycle number, and 1% at >7,500 mg and 2% at >12,500 mg, with a plateau beyond this dose (Figures 1A,B ). (2009) reported a 3.54% rate of severe carboplatin-related hypersensitivity reactions, which is similar to our rate of 2.2%. Necessary cookies enable core functionality. Tx-nave pts ORR was 90%. Oncol. doi: 10.1111/IGC.0b013e3181a418ff, Greene, D. P., Ferriss, J. S., and Jazaeri, A. A spotlight on alkaloid nanoformulations for the treatment of lung cancer. Chemother. Clinical Practice Guidelines Prevention and Management of Dermatological Toxicities Related to Anticancer Agents, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. LUGANO-MADRID, 09 September, 2017 -The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for . Lacouture, V. Sibaud, P.A. 24, 46994707. http://downloads.hindawi.com/journals/mbd/2010/207084.pdf, Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. In 74 of the 75 patients, the hypersensitivity reactions subsided within several minutes to several hours after onset, and the patients recovered without any sequelae. DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --Not intended for U.K. or U.S. based media ESMO 2017 abstract #Erbitux: 576P, 593P, 1068P, 1579. Bethesda, MD 20894, Web Policies PDF | On Jul 1, 2017, J B A G Haanen and others published Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Find, read and . To overcome drug allergy, desensitization has been developed, a novel approach which provides a unique opportunity to protect against anaphylaxis and to improve clinical outcomes. Methods. The ESMO guideline recommends patients receive surveillance by colonoscopy every 3 years beginning at age 25 for MLH1 and MSH2 mutation carriers and age 35 for MSH6 and PMS2 mutation carriers, or . This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. Whether, BRCA 1/2 and HRD-related genes modulate Th2 gene expression and increase specific IgE to carboplatin is still unknown. Genc et al. J Oncol Pract. Adnan A, Acharya S, Alenazy LA, de Las Vecillas L, Giavina Bianchi P, Picard M, Calbache-Gil L, Romero-Pinedo S, Abad A-Molina AC, Kerr W, Pedicone C, Nagai J, Hollers E, Dwyer D, Castells M. J Immunol. Symptoms and signs of hypersensitivity reactions amendable to desensitization. 2022 Dec;11(12):1405-1418. doi: 10.1002/cpdd.1183. Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. PH IV/PH FDC SC for HER2-positive BC were well tolerated, with few grade 3 anaphylaxis/hypersensitivity events reported with PH IV and no grade 3 related events with PH FDC SC. Educate. There is evidence that inhibitory mechanisms blocking IgE/antigen mast cell activation are active during desensitization, enhancing safety. Only 2 women are Mongolians and the other 733 women are Asian Taiwanese. Severe carboplatin-related hypersensitivity reactions are uncommon. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. 17 This dose reduction is due to the ability of both aprepitant and netupitant to inhibit the metabolism of dexamethasone leading to higher . All funding for this site is provided directly by ESMO. Guidelines | ESMO Ke. Acquisition of data: Y-HT, S-PL, Y-CC, Y-LC. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. sharing sensitive information, make sure youre on a federal (2011) found that the number of treatment cycles with platinum-containing antineoplastic agents significantly correlates with the incidence of related hypersensitivity reactions. Author Information. Utilizing Biologics in Drug Desensitization. also successfully developed a platinum desensitization protocol for patients with either a positive carboplatin skin test or a history of prior carboplatin hypersensitivity (Altwerger et al., 2017). Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. J. Gynecol. Unauthorized use of these marks is strictly prohibited. Such reactions were scored according to the Common Terminology Criteria for Adverse Events version 4.03, with severity assessed as mild (grades 1 and 2) or severe (grades 3 and 4). MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2017 Ann Oncol (2017) 28 (suppl 4): iv100iv118.Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan. (1994). Shah et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. J Exp Clin Cancer Res (2011) 30:93.10.1186/1756-9966-30-93 J. Clin. Among these 75 women, 16 (21.3%) experienced severe hypersensitivity reactions (grades 3 and 4). Similarly, a Japanese study found that carboplatin hypersensitivity occurred at a median of 11.5 cycles and 8,084.5 mg (Koshiba et al., 2009). 2022 Apr 26;14(4):e24515. 2023 Feb 15;24(4):3886. doi: 10.3390/ijms24043886. Int J Mol Sci. J Investig Allergol Clin Immunol. Bayer to Highlight New Research at ESMO 2017 Congress The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically relevant topics and are produced by 20-40 key experts in the field. Blood. A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., et al. Unable to load your collection due to an error, Unable to load your delegates due to an error. The ESMO Congress is the most influential annual meeting for oncology professionals in Europe. Upon the occurrence of symptoms and signs, carboplatin infusion was immediately stopped. hypersensitivity and pneumonitis not otherwise specified. 2012;97:217-33. doi: 10.1159/000335637. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population.
Ontrac Shipment Delayed Delivery Date Updated, Interval Notation Domain And Range, Stinger Sc4rad Instructions, Yuma Checkpoint Closed, Caroline Kennedy House Nyc, Articles E